Drug Trial Radar · NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
440
Planned (sponsor's estimate)
Start
Mar 12, 2025
Primary completion
Dec 30, 2027
Study completion Jun 22, 2032
Sponsor
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Celgene Corporation
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions
BMS-986393Drug
Specified dose on specified days
CyclophosphamideDrug
Specified dose on specified days
FludarabineDrug
Specified dose on specified days
DaratumumabDrug
Specified dose on specified days
PomalidomideDrug
Specified dose on specified days
DexamethasoneDrug
Specified dose on specified days
CarfilzomibDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to 5 years after the last participant is randomized
- Minimal residual disease (MRD)-negativity in complete response (CR)Time frame: Up to 1 year after the last participant is randomized
Locations
141 sites in 31 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
UCLA Hematology/Oncology - Santa Monica
Los Angeles, California · Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center
Orange, California · Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
Baptist MD Anderson Cancer Center
Jacksonville, Florida · Recruiting
University of Miami Hospital and Clinics, Sylvester Cancer Center
Miami, Florida · Recruiting
Local Institution - 0228
Orlando, Florida · Withdrawn
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
Louisiana State University Health Sciences Shreveport
Shreveport, Louisiana · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
Local Institution - 0219
Minneapolis, Minnesota · Withdrawn
Weill Cornell Medical College
New York, New York · Recruiting
Local Institution - 0221
Stony Brook, New York · Withdrawn
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Local Institution - 0097
Philadelphia, Pennsylvania · Active not recruiting
AHN West Penn Hospital
Pittsburgh, Pennsylvania · Recruiting
Local Institution - 0227
Charleston, South Carolina · Withdrawn
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Hospital Italiano de Buenos Aires
ABB, Buenos Aires F.D., Argentina · Recruiting
Local Institution - 0214
ABB, Buenos Aires F.D., Argentina · Withdrawn
Hospital Aleman
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Local Institution - 0142
Camperdown, New South Wales, Australia · Active not recruiting
Local Institution - 0190
Liverpool, New South Wales, Australia · Active not recruiting
Local Institution - 0140
Brisbane, Queensland, Australia · Active not recruiting
Local Institution - 0139
Adelaide, South Australia, Australia · Active not recruiting
Local Institution - 0143
Clayton, Victoria, Australia · Active not recruiting
Local Institution - 0138
Melbourne, Victoria, Australia · Active not recruiting
Local Institution - 0191
Melbourne, Victoria, Australia · Active not recruiting
Local Institution - 0141
Murdoch, Western Australia, Australia · Active not recruiting
Hanusch-Krankenhaus
Vienna, Austria · Recruiting
Ordensklinikum Linz GmbH Elisabethinen
Linz, Upper Austria, Austria · Recruiting
Antwerp University Hospital
Edegem, Antwerpen, Belgium · Recruiting
Cliniques universitaires Saint-Luc
Brussels, Bruxelles-Capitale, Région de, Belgium · Recruiting
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne
Yvoir, Namur, Belgium · Recruiting
UZ Gent
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Instituto D'Or de Pesquisa e Ensino (IDOR)
São Paulo, Brazil · Recruiting
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.